Active Surveillance: A Potential Strategy for Select Patients with Small Renal Masses

• Jemal A , SiegelR, XuJ, WardE. Cancer statistics, 2010.CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Chow WH , DevesaSS, WarrenJL, FraumeniJFJr. Rising incidence of renal cell cancer in the United States.JAMA281(17), 1628–1631 (1999).
   PubMed Web of Science ®Google Scholar
• Hollingsworth JM , MillerDC, DaignaultS, HollenbeckBK. Rising incidence of small renal masses: a need to reassess treatment effect.J. Natl Cancer Inst.98(18), 1331–1334 (2006).
   PubMedGoogle Scholar
• Kane CJ , MallinK, RitcheyJ, CooperbergMR, CarrollPR. Renal cell cancer stage migration: analysis of the National Cancer Data Base.Cancer113(1), 78–83 (2008).
   PubMed Web of Science ®Google Scholar
• Cooperberg MR , MallinK, RitcheyJ, VillaltaJD, CarrollPR, KaneCJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004.J. Urol.179(6), 2131–2135 (2008).
   PubMed Web of Science ®Google Scholar
• Jayson M , SandersH. Increased incidence of serendipitously discovered renal cell carcinoma.Urology51(2), 203–205 (1998).
   PubMed Web of Science ®Google Scholar
• Kutikov A , FossettLK, RamchandaniPet al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology 68(4), 737–740 (2006).
   PubMed Web of Science ®Google Scholar
• Crispen PL , BoorjianSA, LohseCMet al. Outcomes following partial nephrectomy by tumor size. J. Urol. 180(5), 1912–1917 (2008).
   PubMed Web of Science ®Google Scholar
• Remzi M , OzsoyM, KlinglerHCet al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J. Urol. 176(3), 896–899 (2006).
   PubMed Web of Science ®Google Scholar
• Hollenbeck BK , TaubDA, MillerDC, DunnRL, WeiJT. National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization?Urology67(2), 254–259 (2006).
   PubMed Web of Science ®Google Scholar
• Huang WC , LeveyAS, SerioAMet al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 7(9), 735–740 (2006).
   PubMed Web of Science ®Google Scholar
• McKiernan J , SimmonsR, KatzJ, RussoP. Natural history of chronic renal insufficiency after partial and radical nephrectomy.Urology59(6), 816–820 (2002).
   PubMed Web of Science ®Google Scholar
• Go AS , ChertowGM, FanD, McCullochCE, HsuCY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N. Engl. J. Med.351(13), 1296–305 (2004).
   PubMed Web of Science ®Google Scholar
• Huang WC , ElkinEB, LeveyAS, JangTL, RussoP. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors – is there a difference in mortality and cardiovascular outcomes?J. Urol.181(1), 55–61, discussion 61–62 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson RH , BoorjianSA, LohseCMet al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J. Urol. 179(2), 468–471 (2008).
   PubMed Web of Science ®Google Scholar
• Gill IS , KavoussiLR, LaneBRet al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J. Urol. 178(1), 41–46 (2007).
   PubMed Web of Science ®Google Scholar
• Van Poppel H , Da PozzoL, AlbrechtWet al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur. Urol. 59(4), 543–552 (2011).
   PubMed Web of Science ®Google Scholar
• Simhan J , SmaldoneMC, TsaiKJet al. Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur. Urol. 60(4), 724–730 (2011) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Lane BR , GillIS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy.J. Urol.183(2), 473–479 (2010).
   PubMed Web of Science ®Google Scholar
• Scoll BJ , UzzoRG, ChenDYet al. Robot-assisted partial nephrectomy: a large single-institutional experience. Urology 75(6), 1328–1334 (2010).
   PubMed Web of Science ®Google Scholar
• Campbell SC , NovickAC, BelldegrunAet al. Guideline for management of the clinical T1 renal mass. J. Urol. 182(4), 1271–1279 (2009).
   PubMed Web of Science ®Google Scholar
• Kutikov A , KunkleDA, UzzoRG. Focal therapy for kidney cancer: a systematic review.Curr. Opin Urol.19(2), 148–153 (2009).
   PubMed Web of Science ®Google Scholar
• Kunkle DA , EglestonBL, UzzoRG. Excise, ablate or observe: the small renal mass dilemma – a meta-analysis and review.J. Urol.179(4), 1227–1233 (2008).
   PubMed Web of Science ®Google Scholar
• Kutikov A , EglestonBL, WongYN, UzzoRG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.J. Clin. Oncol.28(2), 311–317 (2010).
   PubMed Web of Science ®Google Scholar
• Welch HG , BlackWC. Overdiagnosis in cancer.J. Natl Cancer Inst.102(9), 605–613 (2010).
   PubMedGoogle Scholar
• Dall’Era MA , CooperbergMR, ChanJMet al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112(8), 1650–1659 (2008).
   PubMed Web of Science ®Google Scholar
• Wilt TJ , BrawerMK, BarryMJet al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp. Clin. Trials 30(1), 81–87 (2009).
   PubMed Web of Science ®Google Scholar
• Frank I , BluteML, ChevilleJC, LohseCM, WeaverAL, ZinckeH. Solid renal tumors: an analysis of pathological features related to tumor size.J. Urol.170(6 Pt 1), 2217–2220 (2003).
   PubMed Web of Science ®Google Scholar
• Thompson RH , KurtaJM, KaagMet al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J. Urol. 181(5), 2033–2036 (2009).
   PubMed Web of Science ®Google Scholar
• Rothman J , EglestonB, WongYN, IffrigK, LebovitchS, UzzoRG. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis.J. Urol.181(1), 29–33 (2009).
   PubMed Web of Science ®Google Scholar
• Kunkle DA , CrispenPL, LiT, UzzoRG. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses.J. Urol.177(5), 1692–1626 (2007).
   PubMed Web of Science ®Google Scholar
• Nguyen MM , GillIS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality.J. Urol.181(3), 1020–1027 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson RH , HillJR, BabayevYet al. Metastatic renal cell carcinoma risk according to tumor size. J. Urol. 182(1), 41–45 (2009).
   PubMed Web of Science ®Google Scholar
• Duffey BG , ChoykePL, GlennGet al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J. Urol. 172(1), 63–65 (2004).
   PubMed Web of Science ®Google Scholar
• Lane BR , AbouassalyR, GaoTet al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 116(13), 3119–3126 (2010).
   PubMed Web of Science ®Google Scholar
• Arrontes DS , AceneroMJF, GonzalezJIG, MunozMM, AndresPP. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index.J. Urol.179(3), 857–861 (2008).
   PubMed Web of Science ®Google Scholar
• Hollingsworth JM , MillerDC, DaignaultS, HollenbeckBK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis.Cancer109(9), 1763–1768 (2007).
   PubMed Web of Science ®Google Scholar
• Lughezzani G , SunM, BudausL, ThuretR, PerrotteP, KarakiewiczPI. Population-based external validation of a competing-risks nomogram for patients with localized renal cell carcinoma.J. Clin. Oncol.28(18), E99–E300 (2010).
   PubMed Web of Science ®Google Scholar
• Kutikov A , EglestonBL, SmaldoneMC, CanterD, WongYN, UzzoRG. Quantification of competing risks of death with localized renal cell carcinoma (RCC): a comprehensive nomogram incorporating co-morbidities Presented at:American Urologic Association Annual Meeting. Washington, DC, USA, 14–19 May 2011.
   Google Scholar
• Uzzo RG . Renal masses – to treat or not to treat? If that is the question are contemporary biomarkers the answer?J. Urol.180(2), 433–434 (2008).
   PubMed Web of Science ®Google Scholar
• Jeldres C , SunM, LibermanDet al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J. Urol. 182(6), 2585–2589 (2009).
   PubMed Web of Science ®Google Scholar
• Lane BR , BabineauD, KattanMWet al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J. Urol. 178(2), 429–434 (2007).
   PubMed Web of Science ®Google Scholar
• Lane BR , SamplaskiMK, HertsBR, ZhouM, NovickAC, CampbellSC. Renal mass biopsy – a renaissance?J. Urol.179(1), 20–27 (2008).
   PubMed Web of Science ®Google Scholar
• Wang R , WolfJSJr, WoodDPJr, HigginsEJ, HafezKS. Accuracy of percutaneous core biopsy in management of small renal masses.Urology73(3), 586–590, discussion 590–591 (2009).
   PubMed Web of Science ®Google Scholar
• Lechevallier E , AndreM, BarriolDet al. Fine-needle percutaneous biopsy of renal masses with helical CT guidance. Radiology 216(2), 506–510 (2000).
   PubMed Web of Science ®Google Scholar
• Leveridge M , ShiffD, ChungHet al. Small renal mass needle core biopsy: outcomes of non-diagnostic percutaneous biopsy and role of repeat biopsy (abstract 821). J. Urol. 183(4), E321 (2010).
   Web of Science ®Google Scholar
• Blumenfeld AJ , GuruK, FuchsGJ, KimHL. Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade.Urology76(3), 610–613 (2010).
   PubMed Web of Science ®Google Scholar
• Rothman J , CrispenPL, WongYN, Al-SaleemT, FoxE, UzzoRG. Pathologic concordance of sporadic synchronous bilateral renal masses.Urology72(1), 138–142 (2008).
   PubMed Web of Science ®Google Scholar
• Pal SK , KortylewskiM, YuH, FiglinRA. Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.Mol. Cancer Ther.9(12), 3115–3125 (2010).
   PubMed Web of Science ®Google Scholar
• Lawrentschuk N , DavisID, BoltonDM, ScottAM. Functional imaging of renal cell carcinoma.Nat. Rev. Urol.7(5), 258–266 (2010).
   PubMed Web of Science ®Google Scholar
• Lawrentschuk N , ScottAM, DavisID. Potential of imaging biomarkers for characterization of renal masses.Expert Rev. Anticancer Ther.10(6), 781–786 (2010).
   PubMed Web of Science ®Google Scholar
• Divgi CR , Pandit-TaskarN, JungbluthAAet al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a Phase I trial. Lancet Oncol. 8(4), 304–310 (2007).
   PubMed Web of Science ®Google Scholar
• Uzzo RG , RussoP, ChenDet al. The Multicenter Phase III REDECT Trial: a comparative study of 124 I-girentuximab-PET/CT versus diagnostic CT for the pre-operative diagnosis of clear cell renal cell carcinoma (ccRCC). Presented at: American Urologic Association Annual Meeting. San Francisco, CA, USA, 29 May–3 June 2010.
   Google Scholar
• Lane BR , KattanMW. Prognostic models and algorithms in renal cell carcinoma.Urol. Clin. North. Am.35(4), 613–625; VII (2008).
   PubMed Web of Science ®Google Scholar
• Cindolo L , PatardJJ, ChiodiniPet al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104(7), 1362–1371 (2005).
   PubMed Web of Science ®Google Scholar
• Raj GV , ThompsonRH, LeibovichBC, BluteML, RussoP, KattanMW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer.J. Urol.179(6), 2146–2151 (2008).
   PubMed Web of Science ®Google Scholar
• Yaycioglu O , RobertsWW, ChanT, EpsteinJI, MarshallFF, KavoussiLR. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model.Urology58(2), 141–145 (2001).
   PubMed Web of Science ®Google Scholar
• Kutikov A , UzzoRG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth.J. Urol.182(3), 844–853 (2009).
   PubMed Web of Science ®Google Scholar
• Ficarra V , NovaraG, SeccoSet al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur. Urol. 56(5), 786–793 (2009).
   PubMed Web of Science ®Google Scholar
• Simmons MN , ChingCB, SamplaskiMK, ParkCH, GillIS. Kidney tumor location measurement using the C index method.J. Urol.183(5), 1708–1713 (2010).
   PubMed Web of Science ®Google Scholar
• Kutikov A , SmaldoneMC, EglestonBLet al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur. Urol. 60(2), 241–248 (2011).
   PubMed Web of Science ®Google Scholar
• Smaldone MC , KutikovA, EglestonBLet al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer doi: 10.1002/cncr.26369 (2011) (Epub ahead of print).
   Google Scholar
• Crispen PL , ViterboR, BoorjianSA, GreenbergRE, ChenDY, UzzoRG.Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer115(13), 2844–2852 (2009).
   PubMed Web of Science ®Google Scholar
• Ozono S , MiyaoN, IgarashiTet al. Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. Jpn. J. Clin. Oncol. 34(2), 82–85 (2004).
   PubMed Web of Science ®Google Scholar
• Chawla SN , CrispenPL, HanlonAL, GreenbergRE, ChenDY, UzzoRG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature.J. Urol.175(2), 425–431 (2006).
   PubMed Web of Science ®Google Scholar
• Haramis G , MuesAC, RosalesJCet al. Natural history of renal cortical neoplasms during active surveillance with follow-up longer than 5 years. Urology 77(4), 787–791 (2011).
   PubMed Web of Science ®Google Scholar
• Jewett MA , MattarK, BasiukJet al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur. Urol. 60(1), 39–44 (2011).
   PubMed Web of Science ®Google Scholar
• Mason RJ , AbdolellM, TrottierGet al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur. Urol. 59(5), 863–867 (2011).
   PubMed Web of Science ®Google Scholar
• Mues AC , HaramisG, BadaniKet al. Active surveillance for larger (cT1bN0M0 and cT2N0M0) renal cortical neoplasms. Urology 76(3), 620–623 (2010).
   PubMed Web of Science ®Google Scholar
• Siu W , HafezKS, JohnstonWK3rd, WolfJSJr. Growth rates of renal cell carcinoma and oncocytoma under surveillance are similar.Urol Oncol.25(2), 115–119 (2007).
   PubMed Web of Science ®Google Scholar
• Neuzillet Y , LechevallierE, AndreM, DanielL, NahonO, CoulangeC. Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy.Urology66(6), 1181–1185 (2005).
   PubMed Web of Science ®Google Scholar
• Crispen PL , ViterboR, FoxEB, GreenbergRE, ChenDY, UzzoRG. Delayed intervention of sporadic renal masses undergoing active surveillance.Cancer112(5), 1051–1057 (2008).
   PubMed Web of Science ®Google Scholar
• Kunkle DA , CrispenPL, ChenDY, GreenbergRE, UzzoRG. Enhancing renal masses with zero net growth during active surveillance.J. Urol.177(3), 849–853, discussion 53–54 (2007).
   PubMed Web of Science ®Google Scholar
• Bosniak MA , BirnbaumBA, KrinskyGA, WaismanJ. Small renal parenchymal neoplasms: further observations on growth.Radiology197(3), 589–597 (1995).
   PubMed Web of Science ®Google Scholar
• Wehle MJ , ThielDD, PetrouSP, YoungPR, FrankI, KarsteadtN. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy.Urology64(1), 49–52 (2004).
   PubMed Web of Science ®Google Scholar
• Letourneau I , OuimetD, DumontM, PichetteV, LeblancM. Renal replacement in end-stage renal disease patients over 75 years old.Am. J. Nephrol.23(2), 71–77 (2003).
   PubMed Web of Science ®Google Scholar
• Chang SL , CiprianoLE, HarshmanLC, GarberAM, ChungBI. Cost–effectiveness analysis of nephron sparing options for the management of small renal masses.J. Urol.185(5), 1591–1597 (2011).
   PubMed Web of Science ®Google Scholar
• Abouassaly R , YangS, FinelliA, KulkarniGS, AlibhaiSM. What is the best treatment strategy for incidentally detected small renal masses? A decision analysis.BJU Int. doi: 10.1111/j.1464-410X.2011.10115.x (2011) (Epub ahead of print).
   Google Scholar
• Crispen PL , UzzoRG. The natural history of untreated renal masses.BJU Int.99(5 Pt B), 1203–1207 (2007).
   PubMed Web of Science ®Google Scholar
• Fujimoto N , SugitaA, TerasawaY, KatoM. Observations on the growth rate of renal cell carcinoma.Int. J. Urol.2(2), 71–76 (1995).
   PubMedGoogle Scholar
• Oda T , MiyaoN, TakahashiA, YanaseMet al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int. J. Urol. 8(9), 473–477 (2001).
   PubMed Web of Science ®Google Scholar
• Volpe A , PanzarellaT, RendonRA, HaiderMA, KondylisFI, JewettMA. The natural history of incidentally detected small renal masses.Cancer100(4), 738–745 (2004).
   PubMed Web of Science ®Google Scholar
• Kato M , SuzukiT, SuzukiY, TerasawaY, SasanoH, AraiY. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis.J. Urol.172(3), 863–866 (2004).
   PubMed Web of Science ®Google Scholar
• Sowery RD , SiemensDR. Growth characteristics of renal cortical tumors in patients managed by watchful waiting.Can. J. Urol.11(5), 2407–2410 (2004).
   PubMedGoogle Scholar
• Lamb GW , BromwichEJ, VaseyP, AitchisonM. Management of renal masses in patients medically unsuitable for nephrectomy-natural history, complications, and outcome.Urol.64(5), 909–913 (2004).
   PubMed Web of Science ®Google Scholar
• Kouba E , SmithA, McRackanD, WallenEM, PruthiRS. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention.J. Urol.177(2), 466–470 (2007).
   PubMed Web of Science ®Google Scholar
• Abou Youssif T , KassoufW, SteinbergJ, AprikianAG, LaplanteMP, TanguayS. Active surveillance for selected patients with renal masses : updated results with long-term follow-up.Cancer110(5), 1010–1014 (2007).
   PubMed Web of Science ®Google Scholar
• Fernando HS , DuvuruS, HawkyardSJ. Conservative management of renal masses in the elderly: our experience.Int. Urol. Nephrol.39(1), 203–207 (2007).
   PubMed Web of Science ®Google Scholar
• Matsuzaki M , KawanoY, MorikawaH, ShigaY, MurataH, KomatsuH. Conservative management of small renal tumors.Hinyokika Kiyo53(4), 207–211 (2007).
   PubMedGoogle Scholar
• Wong JA , RendonRA. Progression to metastatic disease from a small renal cell carcinoma prospectively followed with an active surveillance protocol.Can. Urol. Assoc. J.1(2), 120–122 (2007).
   PubMed Web of Science ®Google Scholar
• Abouassaly R , LaneBR, NovickAC. Active surveillance of renal masses in elderly patients.J. Urol.180(2), 505–508 (2008).
   PubMed Web of Science ®Google Scholar
• Beisland C , HjelleKM, ReisaeterLA, BostadL. Observation should be considered as an alternative in management of renal masses in older and comorbid patients.Eur. Urol.55(6), 1419–1427 (2009).
   PubMed Web of Science ®Google Scholar
• Rosales JC , HaramisG, MorenoJet al. Active surveillance for renal cortical neoplasms. J. Urol. 183(5), 1698–1702 (2010).
   PubMed Web of Science ®Google Scholar
• Kassouf W , AprikianAG, LaplanteM, TanguayS. Natural history of renal masses followed expectantly.J Urol.171(1), 111–113 (2004).
   Google Scholar

Website

• CancerNomograms www.cancernomograms.com
   Google Scholar